L
Luciene Barra Ribeiro
Publications - 4
Citations - 374
Luciene Barra Ribeiro is an academic researcher. The author has contributed to research in topics: Placebo & Clinical trial. The author has an hindex of 3, co-authored 3 publications receiving 40 citations.
Papers
More filters
Journal ArticleDOI
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
Gilmar Reis,M Helena Vasconcelos,Eduardo Augusto dos Santos Moreira-Silva,Daniela Carla Medeiros Silva,Lehana Thabane,Aline Cruz Milagres,Thiago Santiago Ferreira,Castilho Vitor Quirino dos Santos,Vitoria Helena de Souza Campos,Ana Maria Ribeiro Nogueira,Ana Paula Figueiredo Guimaraes de Almeida,Eduardo Diniz Callegari,Adhemar Dias de Figueiredo Neto,Leonardo Cançado Monteiro Savassi,Maria Izabel Campos Simplicio,Luciene Barra Ribeiro,Rosemary Oliveira,Ofir Harari,Jamie I Forrest,Hinda Ruton,Sheila Sprague,Paula McKay,Alla V. Glushchenko,Craig R. Rayner,Craig R. Rayner,Eric J. Lenze,Angela M. Reiersen,Gordon H. Guyatt,Edward J Mills +28 more
TL;DR: The TOGETHER trial as discussed by the authors evaluated the efficacy of fluvoxamine versus placebo in preventing hospitalisation defined as either retention in a COVID-19 emergency setting or transfer to a tertiary hospital due to CoV-19.
Journal ArticleDOI
Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.
Gilmar Reis,Eduardo Augusto dos Santos Moreira Silva,Daniela Carla Medeiros Silva,Lehana Thabane,Gurmit Singh,Jay J H Park,Jay J H Park,Jamie I Forrest,Jamie I Forrest,Ofir Harari,Castilho Vitor Quirino dos Santos,Ana Paula Figueiredo Guimaraes de Almeida,Adhemar Dias de Figueiredo Neto,Leonardo Cançado Monteiro Savassi,Aline Cruz Milagres,Mauro M. Teixeira,Maria Izabel Campos Simplicio,Luciene Barra Ribeiro,Rosemary Oliveira,Edward J Mills,Together Investigators +20 more
TL;DR: In this paper, a randomized clinical trial was conducted in Brazil to determine whether hydroxychloroquine or lopinavir-ritonavir reduces hospitalization among high-risk patients with early symptomatic COVID-19 in an outpatient setting.
Posted ContentDOI
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalization among patients with covid-19: the together randomized platform clinical trial
Gilmar Reis,Eduardo Augusto dos Santos Moreira Silva,Daniela Carla Medeiros Silva,Lehana Thabane,Aline Cruz Milagres,Thiago Santiago Ferreira,Castilho Vitor Quirino dos Santos,Adhemar Dias de Figueiredo Neto,Eduardo Diniz Callegari,Leonardo Cançado Monteiro Savassi,Vitoria Helena de Souza Campos,Maria Izabel Campos Simplicio,Luciene Barra Ribeiro,Rosemary Oliveira,Ofir Harari,Jamie I Forrest,Hinda Ruton,Sheila Sprague,Paula McKay,Alla V. Glushchenko,Craig R. Rayner,Craig R. Rayner,Eric J. Lenze,Angela M. Reiersen,Gordon H. Guyatt,Edward J Mills +25 more
TL;DR: The TOGETHER randomized platform clinical trial as discussed by the authors evaluated the efficacy of fluvoxamine vs. placebo in preventing either extended emergency room observation or hospitalization due to COVID-19.
Journal ArticleDOI
Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19
Gilmar Reis,Eduardo Augusto dos Santos Moreira Silva,D. C. Medeiros Silva,Lehana Thabane,Vitoria Helena de Souza Campos,Thiago S Ferreira,Castilho Vitor Quirino dos Santos,Leonardo Cançado Monteiro Savassi,Adhemar Dias de Figueiredo Neto,Carina Bitarães,Aline Cruz Milagres,Eduardo Diniz Callegari,Maria Izabel Campos Simplicio,Luciene Barra Ribeiro,Rosemary Oliveira,Ofir Harari,Lindsay A. Wilson,Jamie I Forrest,Hinda Ruton,Sheila Sprague,Paula McKay,Christina M. Guo,Gordon H. Guyatt,Craig R Rayner,David R. Boulware,Nicole Ezer,Todd A. Lee,Emily G. McDonald,Mona Bafadhel,Christopher C Butler,Mark Dybul,Edward J Mills +31 more
TL;DR: In this article , the effects of fluvoxamine alone and inhaled budesonide alone for prevention of disease progression among outpatients with COVID-19 were evaluated at 12 clinical sites in Brazil.